Abiopharma

News list

(10% Negative) Seagen Inc. (SGEN) Announces Delay in occurred Development Timeline Due to Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Oct. 2, 2025, 4:04 p.m.
📋 Seagen Inc. (SGEN) - Clinical Trial Update

Filing Date: 2022-07-26

Accepted: 2022-07-26 06:10:04

Event Type: Clinical Trial Update
Event Details:
Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023) (SGEN) Announces Clinical Trial Update Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023) (SGEN) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: occurred
Clinical Stage: clinical trial
Update Type: Trial Timeline Adjustment
Primary Factors: Regulatory Process
Collaboration: Kenji Yasukawa
Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023)
- CIK: 0001060736
- Ticker Symbol: SGEN
- Period End Date: 2022-07-26
- Document Type: 8-K